CytomX Therapeutics, Inc.
CTMX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $34 | $49 | $48 | $38 |
| Short-Term Investments | $109 | $109 | $32 | $63 |
| Receivables | $2 | $2 | $2 | $3 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $4 | $5 | $5 | $4 |
| Total Curr. Assets | $149 | $165 | $87 | $107 |
| Property Plant & Equip (Net) | $7 | $8 | $9 | $11 |
| Goodwill | $1 | $1 | $1 | $1 |
| Intangibles | $0 | $1 | $1 | $1 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $1 | $1 | $1 | $1 |
| Total NC Assets | $9 | $10 | $12 | $13 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $158 | $175 | $98 | $121 |
| Liabilities | – | – | – | – |
| Payables | $1 | $0 | $0 | $1 |
| Short-Term Debt | $6 | $5 | $5 | $5 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $22 | $33 | $67 |
| Other Curr. Liab. | $35 | $12 | $11 | $12 |
| Total Curr. Liab. | $41 | $39 | $50 | $86 |
| LT Debt | $0 | $1 | $3 | $4 |
| Deferred Rev, NC | $0 | $10 | $16 | $27 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $10 | $4 | $4 | $4 |
| Total NC Liab. | $10 | $16 | $23 | $35 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $6 | $7 | $8 | $9 |
| Total Liabilities | $51 | $55 | $73 | $121 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$682 | -$668 | -$668 | -$692 |
| AOCI | $0 | $0 | -$0 | $0 |
| Other Equity | $790 | $788 | $693 | $691 |
| Total Equity | $107 | $120 | $25 | -$0 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $158 | $175 | $98 | $121 |
| Net Debt | -$29 | -$42 | -$39 | -$29 |